In 2023, current value sales of Rx/reimbursement adult incontinence rose substantially due to a spike in unit prices. Although Rx/reimbursement adult incontinence products are available free of charge through Sweden’s public healthcare system, volume growth has been sluggish since the outbreak of COVID-19. In 2023, significant unit price increases dampened demand pushing volume growth rates below 2022 levels as the inflation rate in the country rose. However, as incontinence problems are typical...

Euromonitor International’s Rx/Reimbursement adult incontinence in Sweden report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2028 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.


Why buy this report?
* Get a detailed picture of the Rx/Reimbursement adult incontinence market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years’ experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.